Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Dorzolamide

A carbonic anhydrase inhibitor given as eye drops, approved in the United States in 1994 for glaucoma and ocular hypertension: it reduces the production of aqueous humour and so lowers the pressure inside the eye. This family brings together the active ingredient, pharmacopoeial impurities, labelled standards, nitrosamines and other impurities.

Did you know?It is considered the first medicine to come from structure-based drug design: it was designed by studying the three-dimensional shape of its target, the enzyme carbonic anhydrase II.

Dorzolamide HydrochlorideGo to the active ingredient →
Dorzolamide-d5Isotopically labelledDorzolamide-d5Cat. No. P-D175-010CAS 1227097-70-2

EDQM standards 3

The official European Pharmacopoeia standards for this family.

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.